These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31254552)

  • 21. Advances in low-frequency ultrasound combined with microbubbles in targeted tumor therapy.
    Wang LY; Zheng SS
    J Zhejiang Univ Sci B; 2019 Apr.; 20(4):291-299. PubMed ID: 30932374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
    Chouaib S; Noman MZ; Kosmatopoulos K; Curran MA
    Oncogene; 2017 Jan; 36(4):439-445. PubMed ID: 27345407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in ultrasound-triggered therapy.
    Yang C; Li Y; Du M; Chen Z
    J Drug Target; 2019 Jan; 27(1):33-50. PubMed ID: 29659307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obstacles to T cell migration in the tumor microenvironment.
    Nicolas-Boluda A; Donnadieu E
    Comp Immunol Microbiol Infect Dis; 2019 Apr; 63():22-30. PubMed ID: 30961814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of Ultrasound Combined with Microbubbles for Cancer Therapy.
    Sharma D; Leong KX; Czarnota GJ
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in non and minimal-invasive transcutaneous delivery of immunotherapy for cancer treatment.
    Nguyen TT; Nguyen TTD; Ta QTH; Vo VG
    Biomed Pharmacother; 2020 Nov; 131():110753. PubMed ID: 33152919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emergence of cancer sono-immunotherapy.
    Yang Y; Cheng Y; Cheng L
    Trends Immunol; 2024 Jul; 45(7):549-563. PubMed ID: 38910097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delivering safer immunotherapies for cancer.
    Milling L; Zhang Y; Irvine DJ
    Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrasound induced cancer immunotherapy.
    Unga J; Hashida M
    Adv Drug Deliv Rev; 2014 Jun; 72():144-53. PubMed ID: 24680708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.
    Kim SJ; Ha GH; Kim SH; Kang CD
    Immunol Invest; 2014; 43(6):517-34. PubMed ID: 24295450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Advances in Engineered Materials for Immunotherapy-Involved Combination Cancer Therapy.
    Liang JL; Luo GF; Chen WH; Zhang XZ
    Adv Mater; 2021 Aug; 33(31):e2007630. PubMed ID: 34050564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmenting the synergies of chemotherapy and immunotherapy through drug delivery.
    Kim J; Manspeaker MP; Thomas SN
    Acta Biomater; 2019 Apr; 88():1-14. PubMed ID: 30769136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrasound and microbubble-mediated drug delivery and immunotherapy.
    Omata D; Munakata L; Maruyama K; Suzuki R
    J Med Ultrason (2001); 2022 Apr; ():. PubMed ID: 35403931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changing the tumor microenvironment: new strategies for immunotherapy.
    Berraondo P; Umansky V; Melero I
    Cancer Res; 2012 Oct; 72(20):5159-64. PubMed ID: 22826606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update.
    Mukhopadhyay D; Ahmed A; Sano C; Awad N; Al Sawaftah N; Husseini GA
    Curr Protein Pept Sci; 2021; 22(6):493-504. PubMed ID: 33583369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-frequency HIFU induced cancer immunotherapy: tempting challenges and potential opportunities.
    Shi G; Zhong M; Ye F; Zhang X
    Cancer Biol Med; 2019 Nov; 16(4):714-728. PubMed ID: 31908890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative Pharmacology: Advancing Development of Effective Immunotherapies.
    Tabrizi M; Zhang D; Ganti V; Azadi G
    AAPS J; 2018 Apr; 20(4):66. PubMed ID: 29704129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.